“Rheumatoid arthritis is an attractive treatment area for pharmaceutical companies, as it is dominated by expensive biologics”
BDC – January 14, 2015 – PharmaKronos
The global rheumatoid arthritis drug market is projected to see steady growth from $15.6 billion in 2013 to $19.3 billion in 2023, with a compound annual growth rate (CAGR) of 2.1%, according to GlobalData.
The latest report by the research and consultancy firm states that in the 10 main markets of the world (United States, France, Germany, Italy, Spain, United Kingdom, Japan, Australia, China and India) the USA had the largest share in 2013 (67%), which they will maintain for the end of 2023, albeit slightly down (65%). GlobalData believes that the expansion of the rheumatoid arthritis treatment market will be driven by an increase in the prevalence of this disease, as well as the anticipated launch of new drugs.
These include 3 interleukin-6 inhibitors, 4 new biologics, 4 Jak inhibitors, and numerous biosimilars. Heather Leach, analyst in Immunology, says: “Rheumatoid arthritis is an attractive treatment area for pharmaceutical companies, as it is dominated by expensive biologics, and the oral Jak inhibitors that will come to market should be only slightly cheaper.
Perhaps the most awaited event is the arrival of biosimilars” even if the lack of guidelines will delay their availability.
